Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cisplatin + gemcitabine + trilaciclib + Medicago H5N1 vaccine
- Development stage
- Unknown
- Lead developer
- Medicago
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
This entry describes a non-existent combination of a four-drug oncology regimen and a pandemic influenza vaccine. The oncology component consists of **tislelizumab** (an anti-PD-1 monoclonal antibody), **cisplatin** and **gemcitabine** (standard chemotherapy agents), and **trilaciclib** (a CDK4/6 inhibitor used to protect bone marrow from chemotherapy-induced toxicity). This specific combination has been investigated for the treatment of advanced urothelial carcinoma (e.g., NCT04863248). The second component, **Medicago-influenza (H5N1)**, refers to a plant-based virus-like particle (VLP) vaccine adjuvanted with aluminium hydroxide, developed by Medicago for the prevention of H5N1 pandemic influenza. There is no clinical or biological rationale for combining these two distinct therapeutic interventions into a single regimen. Medicago ceased operations in early 2023, and development of the H5N1 vaccine was discontinued.
- Brand names
- Cosela
- Other names
- H5 VLP pandemic influenza vaccineH-5 VLP pandemic influenza vaccineH 5 VLP pandemic influenza vaccinePlant-based H5 VLP
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + cisplatin + gemcitabine + trilaciclib + Medicago H5N1 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cisplatin + gemcitabine + trilaciclib + Medicago H5N1 vaccine.